Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Collins, along with Matthew Lau ’25, developed the affordable CRISPRKit to make CRISPR ... gene-editing drug Casgevy, which treats sickle cell anemia, a blood disorder. CRISPR/Cas9 works using ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Doudna spoke about all the new opportunities created by the development of the gene-editing tool CRISPR-Cas9. In March last year, Nice rejected Casgevy for people with severe sickle cell disease.

announced Friday a reimbursement agreement with NHS England for eligible sickle cell disease or SCD patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY (exagamglogene autotemcel).

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...